Tofacitinib treatment of systemic juvenile idiopathic arthritis: a case report and literature review
Tofacitinib has shown good efficacy and safety in the treatment of sJIA patients, effectively controlling disease activity and relieving symptoms. The application of Janus kinase (JAK) inhibitors may offer a new treatment option for this disease.
Authors
- Meifang Zhu
- Zhidan Fan (ORCID: https://orcid.org/0009-0008-2473-2480)
- Haiguo Yu (ORCID: https://orcid.org/0000-0001-8255-9390)
- Xiaohua Zhang (ORCID: https://orcid.org/0000-0001-5845-9787)
- Jing Jin (ORCID: https://orcid.org/0000-0002-1866-8653)
- Peng Zhou (ORCID: https://orcid.org/0000-0002-6441-0987)
- Yan Zhao (ORCID: https://orcid.org/0000-0002-1157-8372)
Institutions
- Second Affiliated Hospital of Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pediatrics
- Published
- 2025-02-13
- DOI
- https://doi.org/10.3389/fped.2025.1482762
- Citations
- 1
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Jiangsu Commission of Health
- National Natural Science Foundation of China